A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis

Ann Rheum Dis. 2005 Mar;64(3):506-7. doi: 10.1136/ard.2004.025015.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Practice Guidelines as Topic
  • Severity of Illness Index*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Infliximab